Abbott Laboratories (ABT)
Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
Tharimmune Inc (THAR)
Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering
Novo Nordisk (NVO)
Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
RenovoRx Inc. (RNXT)
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
Curaleaf Hldgs Inc. (CURLF)
Curaleaf Announces Strong Preliminary Unaudited Fourth Quarter 2025 Results
VolitionRX Limited (VNRX)
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
NovaBay Pharmaceuticals Inc. (NBY)
GSK plc (GLAXF)
LakeShore Biopharma Co., Ltd s (LSBPW)
GSK plc (GLAXF)
AstraZeneca Plc (AZNCF)
Dermata Therapeutics Inc. (DRMA)
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
Precigen Inc (PGEN)
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Coya Therapeutics Inc (COYA)
CoyaTherapeutics - Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders